NCT00859703

Study to Assess Efficacy of Risedronate in Preventing Bone Loss in Postmenopausal Women Treated for Breast Cancer

Randomized, Double-blinded, Placebo Controlled Study to Assess Efficacy of Oral 35 mg Per Week Risedronate in Preventing Bone Loss in Postmenopausal Women With Aromatase Inhibitor Therapy for Breast Cancer.

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 20 (actual)
• Sponsor: Hospices Civils de Lyon · Academic / Other
• Sex: Female
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

Aromatase inhibitor therapy is in France the adjuvant reference treatment for postmenopausal women with early-stage breast cancer. This treatment induces bone loss and a higher risk of fractures. This study aimed to document the effect of bisphosphonate therapy in preventing bone loss and osteoporotic fractures in postmenopausal women with aromatase inhibitor treatment for breast cancer

Conditions

• Breast Cancer
• Menopause
• Osteopenia

Interventions

Type	Name	Description
DRUG	Risedronate	35mg oral risedronate once per week for 24 months
DRUG	Placebo	Placebo 35 mg once a week for 24 months

Timeline

• Start date: 2009-11-01
• Primary completion: 2013-10-01
• Completion: 2013-10-01
• First posted: 2009-03-11
• Last updated: 2013-10-31

Locations

1 site across 1 country: France